Pharmacy Pearls: Comparison of Oral Antivirals for Influenza

January 24th, 2020 | Pharmacy Pearls•Infectious Diseases

According to the CDC, Influenza B/Victoria viruses are predominant nationally, which is unusual for this time of year. H1N1 viruses are the next most common. H3N2 and B/Yamagata viruses are circulating at very low levels. In NYS, influenza is currently categorized as widespread with similar frequency patterns of viral types and subtypes. Influenza appears to be peaking early in NYS with 11,051 confirmed cases of influenza reported thus far compared to just 3,858 confirmed case at this time last year. This month’s pharmacy pearl offers a comparison of oral antivirals for influenza treatment in the outpatient setting along with an update on the expanded indication for baloxavir (Xofluza®).

And of course, it’s not too late to vaccinate.

If you have any questions, please contact our Pharmacy Team.

Taking too long?

Reload document

Open in new tab

Download PDF

ABI Value	Interpretation	Recommendation
Greater than 1.4	Calcification/vessel hardening	Refer to vascular specialist
1.0 - 1.4	Normal	None
0.9 - 1.0	Acceptable	None
0.8 - 0.9	Some arterial disease	Treat risk factor
0.5 - 0.8	Moderate arterial disease	Refer to vascular specialist
Less than 0.5	Severe arterial disease	Refer to vascular specialist

Pharmacy Pearls: Comparison of Oral Antivirals for Influenza

Pharmacy Pearls: Comparison of Oral Antivirals for Influenza

GENERAL COVID-19 INFORMATION